Key Takeaways
- • HealthQuad has secured Rs 550 crore in commitments for its third fund, targeting a total corpus of Rs 1,700 crore with a greenshoe option that could expand it to Rs 2,500 crore, positioning it as a significant growth-stage vehicle in Indian healthcare technology.
- • The fund will focus on early-growth companies across healthtech, medtech, biopharma technology, and new healthcare delivery models, with expected closure by mid-2027, following HealthQuad's separation from co-investor Kois in 2025.
- • HealthQuad's first two funds have deployed capital across 18+ portfolio companies including Qure.ai, Wysa, Redcliffe Labs, and Medikabazaar, with the firm having achieved capital returns through exits, though specific DPI and TVPI metrics remain undisclosed.
- • Quadria Capital has formalized a division of labor within its healthcare platform: Quadria will manage conventional healthcare private equity (hospitals, eye care, dialysis, pharma manufacturing), while HealthQuad Advisors will focus exclusively on technology-led healthcare solutions.
- • HealthQuad Fund III is managed by HealthQuad Advisors, a Quadria Group-owned vehicle led by Sunil Thakur, Amit Varma, and Abrar Mir, with recent additions of Agarwal and Namit Chugh to the leadership team.
Summary
HealthQuad, the healthcare-focused venture capital arm of Quadria Capital, has secured Rs 550 crore in fund commitments for its third investment vehicle, signaling continued institutional appetite for technology-driven healthcare solutions in India. The fund targets a final corpus of Rs 1,700 crore, with a greenshoe option available to expand the total to Rs 2,500 crore. According to Sunil Thakur, cofounder of HealthQuad and partner at Quadria Capital, the fund is expected to reach a final close by mid-2027.
HealthQuad Fund III will be managed by HealthQuad Advisors, a vehicle fully owned by Quadria Group through its principal partners Amit Varma, Abrar Mir, and Thakur. The fund launch follows a mutual separation of Kois and Quadria from HealthQuad in 2025, though Kois and Quadria continue to co-manage the first two funds. The leadership team has been reinforced with the addition of Agarwal and Namit Chugh, while the firm retained core personnel from previous fund management operations.
The new fund represents a continuation of HealthQuad's track record in early-growth healthcare technology investment. Its first two funds have backed 18+ companies spanning diagnostics, mental health, laboratory testing, appointment scheduling, dermatology AI, genomics, and specialized healthcare services. Key portfolio companies include Qure.ai, Wysa, Redcliffe Labs, GoApptiv, Cureskin, Strand Life Sciences, THB, Ekincare, and Medikabazaar. While fund-level performance metrics such as DPI and TVPI remain confidential, Thakur and fellow leaders confirmed that HealthQuad has achieved capital returns through portfolio exits.
The fund launch reflects a strategic expansion of Quadria's broader healthcare private equity platform. Quadria has delineated its investment thesis: Quadria Capital itself will pursue conventional healthcare businesses including hospital chains, eye care, dialysis, and pharmaceutical manufacturing, while HealthQuad will concentrate on technology-led healthcare models such as AI-powered diagnostics, remote patient monitoring, digital tools for hospital and clinician workflows, medtech innovation, biopharma technology, and emerging healthcare delivery platforms. This division enables each vehicle to develop specialized expertise and sourcing capabilities aligned with distinct market segments within Indian healthcare.
HealthQuad Fund III will be managed by HealthQuad Advisors, a vehicle fully owned by Quadria Group through its principal partners Amit Varma, Abrar Mir, and Thakur. The fund launch follows a mutual separation of Kois and Quadria from HealthQuad in 2025, though Kois and Quadria continue to co-manage the first two funds. The leadership team has been reinforced with the addition of Agarwal and Namit Chugh, while the firm retained core personnel from previous fund management operations.
The new fund represents a continuation of HealthQuad's track record in early-growth healthcare technology investment. Its first two funds have backed 18+ companies spanning diagnostics, mental health, laboratory testing, appointment scheduling, dermatology AI, genomics, and specialized healthcare services. Key portfolio companies include Qure.ai, Wysa, Redcliffe Labs, GoApptiv, Cureskin, Strand Life Sciences, THB, Ekincare, and Medikabazaar. While fund-level performance metrics such as DPI and TVPI remain confidential, Thakur and fellow leaders confirmed that HealthQuad has achieved capital returns through portfolio exits.
The fund launch reflects a strategic expansion of Quadria's broader healthcare private equity platform. Quadria has delineated its investment thesis: Quadria Capital itself will pursue conventional healthcare businesses including hospital chains, eye care, dialysis, and pharmaceutical manufacturing, while HealthQuad will concentrate on technology-led healthcare models such as AI-powered diagnostics, remote patient monitoring, digital tools for hospital and clinician workflows, medtech innovation, biopharma technology, and emerging healthcare delivery platforms. This division enables each vehicle to develop specialized expertise and sourcing capabilities aligned with distinct market segments within Indian healthcare.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.